As Infectious Threats Reappear, U.S. Public-Health Cuts Face a Real-World Test
Federal agencies say essential disease monitoring remains intact. Specialists warn that reduced staffing could make emerging threats harder to detect.
Read the ArticleCompass guided to roughly double last year's revenue after acquiring Anywhere Real Estate for $1.6 billion. Most of that doubling is merger arithmetic, not growth, and the earnings that actually matter are a test of whether the integration is working.
Nearly 200 private colleges drew on restricted donor endowments in 2025, mostly for operating expenses rather than the purposes donors specified. A restricted gift is a legally binding promise, not a reserve, and the real wrong is usually not redeployment but doing it without consent.
A strong El Niño is confirmed and building, and the conventional playbook says buy fertilizer, sell food processors, trade the crop spikes. A knowable weather event is precisely the kind that's hardest to profit from, because everyone already knows about it.
Yellow.ai is going public via SPAC with a plan to acquire business-process outsourcing firms and automate them rather than sell software to them. The inversion of the normal software playbook is a sharp bet about where AI's value gets captured in a labor-heavy services market, and a genuinely risky one.
A federal judge certified an investor class action against Five Below, unlocking class-wide damages. Certification decides a procedural question about reliance, not whether the company committed fraud, and the underlying theory alleges a false cause, not a fake number.
Private-equity-backed acquirers now dominate RIA M&A and pay bigger headline numbers, but sellers describe a moral dilemma between the payout and their obligations to clients. The dilemma is largely misframed once you look at how modern earnout structures actually work.
A new in-patient exercise program helped previously ineligible, hospitalized heart-transplant candidates qualify for surgery. It reveals that frailty-based ineligibility is often a gap in the care pathway rather than a fixed fact about the patient, and it raises a hard question about a scarce resource.
CMS finalized a rule eliminating shortcuts that let FDA breakthrough-designated devices skip proof of clinical improvement to earn extra Medicare payments. A separate move speeds coverage instead. Read as a package, it's a deliberate rebalancing, not a simple cut.
Michigan reported the first two U.S. deaths in a cyclospora surge with over 18,000 cases nationally. The source is not one contamination event, the count is both undercounted and unevenly tallied, and the danger concentrates in a vulnerable subgroup the "usually mild" description hides.
Federal agencies say essential disease monitoring remains intact. Specialists warn that reduced staffing could make emerging threats harder to detect.
Read the ArticleEvery article on Mavengity is written by a dedicated topic desk and checked against current market practice.
Home, auto, life, and health coverage, explained clearly and checked against the fine print.
Browse InsuranceRates, refinancing, and first-time buyer strategy, without the jargon lenders assume you already know.
Browse MortgageBudgeting, saving, and everyday money habits that compound. No get-rich-quick promises.
Browse Personal FinanceContracts, consumer rights, and disputes, explained so you know where you stand.
Browse LegalHealth coverage and medical billing, broken down so surprise bills are less likely to surprise you.
Browse HealthcareWe start from public rate filings, regulator guidance, and lender disclosures, not marketing copy.
If a term needs a footnote, we explain it in the sentence instead of hiding it in the fine print.
We flag trade-offs and blind spots, not just the upside, so you get the full picture before you decide.
Mavengity is reader-supported and editorially independent from the products we cover.